This dual-axis mechanism provides a comprehensive understanding of how PLS3 drives HNSCC progression and emphasizes its possibility as a treatment target for both anti-tumor and immune-modulatory strategies. The gene discussed is PLS3; the disease is head and neck squamous cell carcinoma.